Open access
Sep 2026
Ezetimibe Versus Alirocumab and Plaque Vulnerability in Patients with Acute Coronary Syndrome Not Achieving LDL-Cholesterol Target with Statin Therapy: The COMBI-LLT-ACS Randomized Trial
Objective: To compare two lipid-lowering therapy strategies involving Ezetimibe and Alirocumab on the vulnerability of atherosclerotic plaque (AP) in patients with acute coronary syndrome (ACS) not achieving the LDL-cholesterol target while on intensive statin therapy. Methods: Combi-LLT-ACS (Patients receiving combina...
A. Kovalskaya, G. Bikbaeva, D. Duplyakov et al.
· Journal of Clinical Medicine · 0 citations